The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients

2018 ◽  
Vol 27 (3) ◽  
pp. 927-931
Author(s):  
Ana Luísa de Castro Baccarin ◽  
Macilon Nonato Irene ◽  
Daniel de Iracema Gomes Cubero ◽  
Ariana Sales Luz ◽  
Suelen Nastri Castro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients ◽  
Paclitaxel Treatment

scholarly journals Preventive Effect of Cryotherapy on Persistent Chemotherapy-induced Peripheral Neuropathy After Completion of Weekly Paclitaxel Therapy for Breast Cancer

2021 ◽  
Author(s):  
Hideo Shigematsu ◽  
Yuri Kimura ◽  
Tomoko Itagaki ◽  
Daisuke Yasui
Keyword(s):  
Breast Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Control Group ◽  
Lower Grade ◽  
Breast Cancer Patients ◽  
Preventive Effect ◽  
One Year ◽  
Paclitaxel Treatment

Abstract BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is an important adverse event of taxane-based chemotherapy, which can persist in a substantial proportion of patients for years. Cryotherapy therapy is shown to be effective in prevention of CIPN during chemotherapy, but its protective effect on persistent CIPN has not been reported. MethodsCases enrolled in a randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966) were evaluated for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score and Patient Neurotoxicity Questionnaire (PNQ) at more than one year after completion of weekly paclitaxel. ResultsThirty-eight cases were evaluated for persistent CIPN with a median 2.3 (1.3-3.1) years after completion of weekly paclitaxel. The incidence of a significant decrease in FACT-NTX scores was numerically lower in the cryotherapy group compared with the control group (15.8% vs. 36.8%, p = 0.13). There was also a lower grade of PNQ sensory (p = 0.02) and motor (p = 0.17) in the cryotherapy group compared with the control group. ConclusionIn breast cancer patients treated with weekly paclitaxel, cryotherapy resulted in a numerical decrease in the incidence of persistent CIPN at more than one year after completion of weekly paclitaxel treatment.

Retrospective study comparing tolerability of weekly paclitaxel in two group of metastatic breast cancer patients: Age 65 and older compared with younger than age 65.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e20528-e20528
Author(s):  
Agnieszka I. Jagiello Gruszfeld ◽  
Zbigniew Nowecki ◽  
Izabela Lemanska ◽  
Renata Irena Sienkiewicz ◽  
Halina Rudnicka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients

Feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of breast cancer: An experience from India.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11536-e11536
Author(s):  
Mohan Kumar Somashekar ◽  
Murali Subramanian V ◽  
Nirmala Srikantaiah S ◽  
Arul Ponni TR ◽  
Rajeev A G ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Conservative Surgery ◽  
Weekly Paclitaxel ◽  
Severe Toxicity ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Breast Conservative Surgery ◽  
Whole Breast Radiotherapy

e11536 Background: Majority of the breast cancer patients require adjuvant radiotherapy and chemotherapy for better locoregional and distant control. However the sequencing of these is still debatable . Hence concurrent chemo radiation may avoid the delay in either of the adjuvant therapies. Anthracyclines are not used concurrently with radiation because of severe toxicity. Hence the current study was taken to assess the feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of ca breast. Methods: A prospective study was conducted on 22 breast cancer patients, post modified radical mastectomy or breast conservative surgery from November 2008 to April 2010. Chest wall or whole breast radiotherapy was given on Tele Cobalt or Linac for a dose of 50 – 50.4Gy in conventional fractionation. Boost of 16 Gy was given to tumor cavity with photons or electrons for those undergone breast conservative surgery. All patients received Inj.paclitaxel 60 mg/m2 once a week for 5 weeks. After completion of RT, paclitaxel dose was increased to 80mg/m2 for remaining 7 cycles. This was followed by anthracycline based treatment sequentially as per standard adjuvant guidelines. Patients assessed weekly and toxicities graded based on CTC version 03. The minimum follow up was 2 months after completion of chemoradiation. Chi-Square test and Fisher exact test were used to interpret the results with literature. Results: See table below. Skin reaction was more frequent and severe of all toxicities (p=0.003).With available literatures on adjuvant radiation alone the grade III and higher skin reactions are 3% but in our study it is 28% because of which 5/22 (22%) patients had interruption of both chemotherapy and radiation. Conclusions: Concurrent chemoradiation with weekly paclitaxel in adjuvant treatment of ca breast is associated with more skin reactions which may result in significant treatment interruptions. It should be practiced cautiously which requires further randomized control studies to assess the toxicities in detail. [Table: see text]

scholarly journals Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL

2006 ◽  
Vol 17 (1) ◽  
pp. 79-84 ◽  
Author(s):  
F. Di Costanzo ◽  
S. Gasperoni ◽  
P. Papaldo ◽  
D. Bilancia ◽  
L. Manzione ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Dose Finding ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients

scholarly journals Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-6
Author(s):  
Hamid Reza Mirzaei ◽  
Fatemeh Nasrollahi ◽  
Ladan Mohammadi Yeganeh ◽  
Sepideh Jafari Naeini ◽  
Pegah Bikdeli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Hematologic Toxicity ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Grade 3 ◽  
Dose Dense ◽  
Positive Breast Cancer

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. The feasibility of dose-dense epirubicin in combination with cyclophosphamide (EC) followed by weekly paclitaxel as adjuvant chemotherapy in node-positive breast cancer patients was investigated. Methods. All patients were treated with epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) every two weeks for four cycles with daily Pegfilgrastim (G-CSF) that was administered 3–10 days after each cycle of epirubicin and cyclophosphamide infusion which followed by (80 mg/m2) paclitaxel for twelve consecutive weeks. Results. Sixty consecutive patients were analyzed, of whom 57 patients (95%) completed the regimen and no case of toxicity-related death was observed. Grade 3/4 hematologic toxicity was uncommon and the most common grade 3/4 nonhematological adverse event was neuropathy disorders. Conclusions. Dose-dense epirubicin and cyclophosphamide followed by weekly paclitaxel with G-CSF support is a well-tolerated and feasible regimen in node-positive breast cancer patients without serious complications.

Sign in / Sign up

Export Citation Format

Share Document